{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:21Z","timestamp":1793120061743,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lanmic.2026.101448","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:27:09Z","timestamp":1780068429000},"page":"101448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Edward","family":"Gane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9144-742X","authenticated-orcid":false,"given":"Sue","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Luber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-5913","authenticated-orcid":false,"given":"Marie","family":"Bonhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien huey","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2026.101448_bib1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib4","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib6","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jhep.2016.01.028","article-title":"The role of innate immunity in the immunopathology and treatment of HBV infection","volume":"64","author":"Maini","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib8","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101448_bib9","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an immunomodulator in chronic hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101448_bib10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2025.12.006","article-title":"Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyond","volume":"84","author":"Sonneveld","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib11","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0168-8278(25)00308-3","article-title":"GS-010 outcomes of 48 weeks of therapy and subsequent 24-week post-treatment period with tobevibart (vir-3434) and elebsiran (vir-2218) with or without pegylated interferon alfa-2a in chronic hepatitis B virus infection. Findings from the MARCH Study","volume":"82","author":"Gane","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-025-10823-5","article-title":"Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2025","journal-title":"Hepatol Int"},{"key":"10.1016\/j.lanmic.2026.101448_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41591-025-04049-z","article-title":"Elebsiran and PEG-IFN\u03b1 for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial","volume":"32","author":"Wong","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2026.101448_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","article-title":"Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B","volume":"82","author":"Buti","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib15","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.lanmic.2026.101448_bib16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.181067","article-title":"A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses","volume":"9","author":"Hasanpourghadi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.lanmic.2026.101448_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-065X.2009.00783.x","article-title":"The CD160, BTLA, LIGHT\/HVEM pathway: a bidirectional switch regulating T-cell activation","volume":"229","author":"Cai","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.lanmic.2026.101448_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm1704","article-title":"Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses","volume":"14","author":"Lasaro","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2026.101448_bib21","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.4049\/jimmunol.1302029","article-title":"The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion","volume":"193","author":"Zhang","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.lanmic.2026.101448_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.immunol.17.1.51","article-title":"Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses","volume":"17","author":"Yewdell","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.lanmic.2026.101448_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000694","article-title":"HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B","volume":"9","author":"Traum","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.lanmic.2026.101448_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanmic.2026.101448_bib26","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101448_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lanmic.2026.101448_bib28","first-page":"11","article-title":"Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss","volume":"22","author":"Gao","year":"2025","journal-title":"Virol J"},{"key":"10.1016\/j.lanmic.2026.101448_bib29","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.31557\/APJCP.2019.20.8.2239","article-title":"Association between hepatitis B surface antigen levels and the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection: systematic review and meta-analysis","volume":"20","author":"Thi Vo","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.lanmic.2026.101448_bib30","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lanmic.2026.101448_bib31","author":"Wong"},{"key":"10.1016\/j.lanmic.2026.101448_bib32","author":"Lai"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726001035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726001035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:01:52Z","timestamp":1785970912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524726001035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666524726001035"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101448","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101448"}}